Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Researchers create animal model of orthopedic injury-induced hypercoagulability

April 24, 2019

Zydus Cadila announces phase III study of desidustat

April 17, 2019

U.S. researchers present a 5-HT2A receptor inhibitor antibody

April 11, 2019

Phase II results for benralizumab in PDGFRA-negative hypereosinophilic syndrome

April 9, 2019

Sangamo provides clinical development update

April 4, 2019

Enrollment open in phase IIb study of dalcinonacog alfa for hemophilia B

April 4, 2019

Sangamo and Pfizer announce phase I/II interim data for SB-525 gene therapy

April 3, 2019

Blood needs Prozac, too

March 25, 2019

Phase III trials of vadadustat in Japanese patients with anemia due to CKD meet primary endpoint

March 12, 2019

New model of hemophagocytic lymphohistiocytosis points to possible therapeutic strategy

March 6, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.